347 related articles for article (PubMed ID: 34108318)
1. [Current treatment of paroxysmal nocturnal hemoglobinuria and prospects for new therapeutic agents in the future].
Nishimura JI
Rinsho Ketsueki; 2021; 62(5):378-387. PubMed ID: 34108318
[TBL] [Abstract][Full Text] [Related]
2. [Novel therapeutics for paroxysmal nocturnal hemoglobinuria].
Nishimura JI
Rinsho Ketsueki; 2021; 62(5):463-471. PubMed ID: 34108330
[TBL] [Abstract][Full Text] [Related]
3. Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT.
Risitano AM; Marotta S; Ricci P; Marano L; Frieri C; Cacace F; Sica M; Kulasekararaj A; Calado RT; Scheinberg P; Notaro R; Peffault de Latour R
Front Immunol; 2019; 10():1157. PubMed ID: 31258525
[TBL] [Abstract][Full Text] [Related]
4. Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies.
Risitano AM
Adv Exp Med Biol; 2013; 735():155-72. PubMed ID: 23402025
[TBL] [Abstract][Full Text] [Related]
5. The complement alternative pathway in paroxysmal nocturnal hemoglobinuria: From a pathogenic mechanism to a therapeutic target.
Risitano AM; Frieri C; Urciuoli E; Marano L
Immunol Rev; 2023 Jan; 313(1):262-278. PubMed ID: 36110036
[TBL] [Abstract][Full Text] [Related]
6. [Antibody therapy for paroxysmal nocturnal hemoglobinuria].
Nishimura JI
Rinsho Ketsueki; 2020; 61(8):929-936. PubMed ID: 32908057
[TBL] [Abstract][Full Text] [Related]
7. Complement inhibition in paroxysmal nocturnal hemoglobinuria: From biology to therapy.
Versino F; Fattizzo B
Int J Lab Hematol; 2024 May; 46 Suppl 1():43-54. PubMed ID: 38622956
[TBL] [Abstract][Full Text] [Related]
8. [Novel anti-complement therapeutics for hemolytic anemia].
Nishimura JI
Rinsho Ketsueki; 2023; 64(6):466-473. PubMed ID: 37407469
[TBL] [Abstract][Full Text] [Related]
9. Emerging drugs for the treatment of paroxysmal nocturnal hemoglobinuria.
Frieri C; Peffault de Latour R; Sicre De Fontbrune F
Expert Opin Emerg Drugs; 2022 Mar; 27(1):33-43. PubMed ID: 35078384
[TBL] [Abstract][Full Text] [Related]
10. Safety of current treatments for paroxysmal nocturnal hemoglobinuria.
Lee SE; Lee JW
Expert Opin Drug Saf; 2021 Feb; 20(2):171-179. PubMed ID: 33249943
[No Abstract] [Full Text] [Related]
11. Achievements and limitations of complement inhibition by eculizumab in paroxysmal nocturnal hemoglobinuria: the role of complement component 3.
Risitano AM; Perna F; Selleri C
Mini Rev Med Chem; 2011 Jun; 11(6):528-35. PubMed ID: 21561403
[TBL] [Abstract][Full Text] [Related]
12. Extravascular hemolysis and complement consumption in Paroxysmal Nocturnal Hemoglobinuria patients undergoing eculizumab treatment.
Subías Hidalgo M; Martin Merinero H; López A; Anter J; García SP; Ataúlfo Gonzalez-Fernández F; Forés R; Lopez-Trascasa M; Villegas A; Ojeda E; Rodríguez de Córdoba S
Immunobiology; 2017 Feb; 222(2):363-371. PubMed ID: 27644115
[TBL] [Abstract][Full Text] [Related]
13. Hemolytic paroxysmal nocturnal hemoglobinuria: 20 years of medical progress.
Peffault de Latour R; Hosokawa K; Risitano AM
Semin Hematol; 2022 Jan; 59(1):38-46. PubMed ID: 35491057
[TBL] [Abstract][Full Text] [Related]
14. Paroxysmal nocturnal hemoglobinuria and the age of therapeutic complement inhibition.
Varela JC; Brodsky RA
Expert Rev Clin Immunol; 2013 Nov; 9(11):1113-24. PubMed ID: 24168416
[TBL] [Abstract][Full Text] [Related]
15. Toward complement inhibition 2.0: Next generation anticomplement agents for paroxysmal nocturnal hemoglobinuria.
Risitano AM; Marotta S
Am J Hematol; 2018 Aug; 93(4):564-577. PubMed ID: 29314145
[TBL] [Abstract][Full Text] [Related]
16. Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Yuan X; Gavriilaki E; Thanassi JA; Yang G; Baines AC; Podos SD; Huang Y; Huang M; Brodsky RA
Haematologica; 2017 Mar; 102(3):466-475. PubMed ID: 27810992
[TBL] [Abstract][Full Text] [Related]
17. Cost burden of breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria receiving ravulizumab versus eculizumab.
Tomazos I; Sierra JR; Johnston KM; Cheung A; Brodsky RA; Weitz IC
Hematology; 2020 Dec; 25(1):327-334. PubMed ID: 32856539
[No Abstract] [Full Text] [Related]
18. Ravulizumab for the treatment of paroxysmal nocturnal hemoglobinuria.
Lee JW; Kulasekararaj AG
Expert Opin Biol Ther; 2020 Mar; 20(3):227-237. PubMed ID: 32011183
[No Abstract] [Full Text] [Related]
19. Evaluating ravulizumab for the treatment of children and adolescents with paroxysmal nocturnal hemoglobinuria.
Yoo JJ; Chonat S
Expert Rev Hematol; 2022 May; 15(5):385-392. PubMed ID: 35502699
[TBL] [Abstract][Full Text] [Related]
20. Biomarkers and laboratory assessments for monitoring the treatment of patients with paroxysmal nocturnal hemoglobinuria: Differences between terminal and proximal complement inhibition.
Kulasekararaj AG; Kuter DJ; Griffin M; Weitz IC; Röth A
Blood Rev; 2023 May; 59():101041. PubMed ID: 36732204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
